Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/34104
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2018-09-27T06:58:14Z-
dc.date.available2018-09-27T06:58:14Z-
dc.date.issued2011-
dc.identifier.citationBorg, N. (2011). Molecular biomarkers associated with mutant BRCAl breast cancer patients (Master's dissertation).en_GB
dc.identifier.urihttps://www.um.edu.mt/library/oar//handle/123456789/34104-
dc.descriptionM.SC.BIOMED.SCI.-
dc.description.abstractThe presence of mutations in the BRCA1 gene has been linked to a worse overall prognosis in the case of breast cancer. Furthermore, its mutational status has been linked to susceptibility or resistance to certain adjuvant therapies used in the treatment of the cancer. This study aims at investigating the feasibility of using phospho-Akt (Serine-473) status as a biomarker for mutant BRCA1 gene and generation of a cellular model for the measurement of Akt activation with respect to BRCA1 mutational status. The use of p-Akt as a biomarker is supported by other studies which showed that inhibition of BRCA1 activity leads to increased phosphorylation of Akt (Xiang, et aI., 2008). Formalin-fixed paraffin-embedded (FFPE) triple negative breast cancer samples were stained with an antibody raised against phosphorylated Ser-473 in Akt (p-Akt (S473)) and an attempt was made to correlate the intensity of staining with the presence of mutations in the BRCA1 gene. A subset of triple negative breast cancer cases (53%) was found to have high p-Akt. Cases with high Akt activation may derive greater benefit from therapies targeting the Akt/mTor pathway. This is supported by the finding that FTY720 (at l/µM), an activator of PP2A (a phosphatase that inhibits Akt activity) suppresses Akt activation in MCF-7 and HCC1937 cells stimulated by IGF-1 (a stimulator of Akt), indicating that p-Akt (S473) is a potential predictive biomarker. Mutational analysis of triple negative breast cancers has revealed the presence of two novel . mutations: IVS2+38insTA in the second intron of BR CA 1, and 5384G>T in exon 20. Further studies are required to investigate the function of the identified mutations in BRCA1 and their significance in disease.en_GB
dc.language.isoenen_GB
dc.rightsinfo:eu-repo/semantics/restrictedAccessen_GB
dc.subjectBRCA genesen_GB
dc.subjectTumor suppressor proteinsen_GB
dc.subjectMolecular biologyen_GB
dc.titleMolecular biomarkers associated with mutant BRCAl breast cancer patientsen_GB
dc.typemasterThesisen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holderen_GB
dc.publisher.institutionUniversity of Maltaen_GB
dc.publisher.departmentFaculty of Medicine and Surgery. Department of Pathologyen_GB
dc.contributor.supervisorGrech, Godfrey-
dc.contributor.supervisorScerri, Christian-
dc.description.reviewedN/Aen_GB
dc.contributor.creatorBorg, Nigel-
Appears in Collections:Dissertations - FacM&S - 2011
Dissertations - FacM&SPat - 2011

Files in This Item:
File Description SizeFormat 
Borg_Nigel_Molecular Biomarkers Associated with Mutant BRCA1.pdf
  Restricted Access
8.48 MBAdobe PDFView/Open Request a copy


Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.